Knowledge

Across topics and issues, borders and industries, we have the thought leadership you need to stay ahead of changes in the law.

Across topics and issues, borders and industries, we have the thought leadership you need to stay ahead of changes in the law.

Follow us:

Publications

News

COVID-19 IP update: Intellectual Property Office developments (UK & EPO updated)

The Hogan Lovells IP & Media Technology team is tracking the changes being made by intellectual property offices around the world in response to the coronavirus so we can keep you...

News

COVID-19 IP update: impact on litigation

The Hogan Lovells IP & Media Technology team is closely following the impact of COVID-19 on the operation of Courts around the world and what this means in practice for clients...

News

COVID-19 and emergency inventions

As the spread of COVID-19 accelerates across the globe, everyone wants to find a way to tackle the pandemic, from Governments asking manufacturers to urgently make vital equipment to...

News

The impact of COVID-19 on clinical trials and countermeasure development in Japan

On 19 March 2020, the Ministry of Health, Labour and Welfare of Japan (MHLW) issued a notice announcing a waiver of the statutorily-required waiting period after submitting a request for...

News

Japan considers utilization of “compassionate use” exception to fast-track COVID-19 treatments

While several drugs are being studied in Japan to treat COVID-19, none have yet been approved. However, reports indicate remdesivir, a drug developed by as a treatment for Ebola virus...

News

Japan waives clinical trial waiting period for COVID-19 treatments

On 19 March 2020, the Ministry of Health, Labour and Welfare of Japan (MHLW) issued a notice announcing a waiver of the statutorily-required waiting period after submitting a request for...

Insights

Hogan Lovells’ Standard Essential Patent Update – May 2019
Registered Content

Hogan Lovells’ Standard Essential Patent (SEP) Update reports on recent news and case decisions from jurisdictions including China, France, Germany, Italy, Japan, the Netherlands,...

News

Life Sciences and Health Care Horizons 2019 publication: IP in the mix

Innovation in the life sciences and health care industries is occurring at a dizzying pace. Five years ago, anti-PD-1 antibodies from Merck and BMS had yet to be approved, CAR-T therapies ...

Insights

Hogan Lovells’ Standard Essential Patent Update – February 2019
Registered Content

Hogan Lovells’ Standard Essential Patent (SEP) Update reports on recent news and case decisions from jurisdictions including China, France, Germany, Italy, Japan, the Netherlands,...

Loading data